EP. 4 Patient Case Review: Investigating Treatment Profiles, Exploring the Role of Treatment Adherence and Drug Class Selection Considerations
EP. 6 Managing Treatment Changes in Older Adults with T2D: Approaches, Burdens, and Benefits of Combination Therapy
EP. 7 Optimizing Treatment: Expert Insights on Streamlining and Deprescribing for Older Adults with T2D
EP. 8 Patient Case 2: Tailoring Treatment for Complex Needs, Incorporating Cardiovascular, Weight, and Renal Considerations
September 24th, 2026FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 DiabetesThe FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes. Read more
September 23rd, 2026Type 2 Diabetes, Genetic Risk Linked to MASLD Cirrhosis Before Age 50New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.Read more
September 17th, 2026FDA Approves Finerenone for CKD Associated With Type 1 DiabetesFinerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.Read more
September 15th, 2026FDA Clears Beta Bionics’ Mint Reusable Insulin Patch PumpThe US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes. Read more
August 28th, 2026FDA Expands Tirzepatide Label for Cardiovascular Risk Reduction in Type 2 DiabetesTirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.Read more
August 25th, 2026FDA Authorizes First Wearable Device to Continuously Monitor Glucose, KetonesFDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.Read more